Press
Kai Peterson joins NeuroLight as Director of Non-dilutive Funding and Grants
NeuroLight, Inc. is pleased to announce the appointment of Kai Peterson as our new Director of Non-dilutive Funding and Grants.
NeuroLight Presents Groundbreaking Insights on Sleep Stage Transitions at ASCS 2025
Pomona, New York — April 2025 — NeuroLight, Inc. is pleased to announce the successful presentation of its latest research at the Annual Advances in Sleep and Circadian Science (ASCS) Conference held in Florida by the Sleep Research Society (SRS). Dr. Antony Passaro, NeuroLight’s Lead
Prof. Jeffry Lansman Joins Advisory Board of NeuroLight, Inc.
Pomona, New York — February 19, 2025 — NeuroLight, Inc., a pioneering neuromodulation medical device company, today announced the appointment of Jeffry B. Lansman, Ph.D. to its Advisory Board. Dr. Lansman is a Professor Emeritus of Cellular & Molecular Pharmacology in the School of Medicine,
Dr. Alexander Kott Joins Advisory Board of NeuroLight, Inc.
Pomona, New York — December 2, 2024 — NeuroLight, Inc., a pioneering neuromodulation medical device company, today announced that former Chief Scientist of the US Army Research Laboratory, Dr. Alexander Kott, Ph.D., joined its Advisory Board. NeuroLight is revolutionizing brain sensory stimulation technology, enabling the
Dr. Scott Parazynski Joins Advisory Board of NeuroLight, Inc.
Dr. Scott Parazynski, an astronaut, inventor, and medical expert, has joined the Advisory Board of NeuroLight, Inc., a neuromodulation medical device company We are thrilled to welcome Dr. Parazynski to our Advisory Board. His unique blend of scientific, medical, and entrepreneurial expertise will provide invaluable
NeuroLight, Inc. Successfully Completes Phase I NSF/SBIR Grant, Paving the Way for Innovative Sleep Therapy
NeuroLight, Inc. has successfully completed its Phase I NSF/SBIR grant and submitted Outcomes Report, detailing progress in developing neromod sleep technology.
NeuroLight Awarded a Patent for Groundbreaking Neuromodulation Technology
US Patent No. 11,413,425 is issued for non-pharmaceutical treatment of coronasomnia with neuromodulation POMONA, NEW YORK, UNITED STATES, January 31, 2024 — NeuroLight, Inc. today announced the recent grant of US Patent No. 11,413,425 for the treatment of coronasomnia with neuromodulation. This patent covers a novel method of
US Patent Granted to NeuroLight for Technology to Induce Sleep by Neuromodulation
NeuroLight Aims to Use its Technology for Transplanting Mental States to Treat Insomnia and Other Sleep Disorders POMONA, NEW YORK, USA, January 11, 2024 — NeuroLight, Inc., a leading innovator in the field of neuromodulation, is thrilled to announce the recent grant of a United
NeuroLight Has Been Awarded another US Patent on Technology to Enhance Emotional Response
NeuroLight, a neuromodulation company, first to develop technology for transplanting brain states, received a patent on technology to enhance emotional response
NeuroLight Has Been Awarded US Patent on Technology to Enhance Emotional Response
Pomona, N.Y., August 10, 2023—NeuroLight, Inc., a neuromodulation company, announced that it was awarded a US patent on the technology to enhance emotional response. US Patent No. 11,318,277, titled “Method and apparatus for neuroenhancement to enhance emotional response,” was issued to Neuroenhancement Lab, LLC, the
NeuroLight Awarded Competitive Grant from the U.S. National Science Foundation
NeuroLight, Inc., a neuromodulation company first to develop technology for transplanting mental states™, awarded grant from the U.S. National Science Foundation (NSF)
Neuroenhancement Lab, Inc. Announces Rebrand as NeuroLight
Neuroenhancement Lab, Inc., a neuromodulation company first to develop technology for transplanting mental states™ from one person to another, rebrands itself as NeuroLight.
